Report
Gary Waanders

MEDIGENE - BUY | EUR16.2 vs. 16.1(+83%) Medigene 2018 results – progress and potential

MEDIGENE - BUY | EUR16.2 vs. 16.1(+83%)
Medigene 2018 results – progress and potential

Solid 2018 Financial results – restatements but no surprises
Pipeline filling and progressing
Collaborations expanding
Positive profile for 2019
Underlying
Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Gary Waanders

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch